Navigation Links
Trastuzumab therapy effective for Breast cancer patients with Her-2/neu positive

Researchers Edith Perez and Edward Romond reported from two separate trials that Breast cancer patients with Her2-positive were effectively treated with Herceptin therapy using trastuzumab. //The results of their study were published in the journal The New England Journal of Medicine. The researchers compiled results from two clinical trials, which compared patients getting only chemotherapy with patients receiving both chemotherapy and trastuzumab. Use of Herceptin drug has become very important as more than one million women are diagnosed of breast cancer each year around the world and of which 25% of patients have Her-2/neu positive status. Her-2 positive patients do not respond positively and effectively to routine chemotherapy drugs, which require trastuzumab therapy.

The study recruited a total of 3,351 patients of which 2,043 patients were enrolled in National Surgical Adjuvant Breast and Bowel Project (NSABP) and 1,633 patients were enrolled in two groups of North Central Cancer Treatment Group (NCCTG) trial N9831. The study results showed that out of 1,679 control patients 261 patients developed recurrence breast cancer disease compared to 133 in the group receiving trastuzumab. At three years, 90.4 percent of women receiving trastuzumab were disease free, compared to 81.5 percent of women in the control group. There also was a measurable reduction in the development of other non-breast primary cancers in the B-31 trial for women receiving trastuzumab. Overall survival also appeared to be impacted, with only 62 deaths in the trastuzumab group as compared with 92 in the control group.

NCCTG Trial: NCCTG trial was investigated by Dr. Perez and his team, the clinical trial compared three chemotherapy drugs treatment of which two of the drug treatments contained trastuzumab therapy with one dosage concurrent with weekly paclitaxel, the other after completion of paclitaxel.

NSABP Trial: Investigators compared treatment with o ne chemotherapy regimen against the same chemotherapy regimen of weekly trastuzumab and weekly paclitaxel. Dr. Perez, Co-director Mayo Clinic’s Multidisciplinary Breast Clinic said, “When we started this study, I knew in my heart results would be positive, but this by far exceeded my expectations and now there is convincing evidence that women with Her-2/neu positive breast cancer can now be treated more effectively.”

Source: News wis
'"/>




Related medicine news :

1. Acupuncture May Help Chemotherapy Side Effects
2. Antioxidants protect health tissue in people undergoing radiation therapy.
3. Distraction therapy found very effective in postoperative patients
4. Acupuncture superseeds massage therapy for short term relief of pain
5. Ovarian cancer in relationship with Hormone therapy
6. New therapy better at increasing bone density
7. Gene therapy - Aim to improve blood flow
8. Gene therapy restores sight
9. Heat therapy relieves back pain
10. Radiotherapy helps in colon cancer
11. New therapy for pimples
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/19/2017)... ... August 19, 2017 , ... Parker at Stonegate, an assisted ... passionate employees, caregivers, volunteers, thought leaders, researchers, educators and partners leading the way ... time to refresh the carpeting with the goal of maintaining the same precise ...
(Date:8/18/2017)... ... ... More than 20,000 pairs of shoes made their way across the Atlantic this ... conjoined the passions of an NBA star, a Liberty University student, and an LU ... save lives from the rampant infections transmitted through the soil. , AMERICAN SOLES , ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... of “Vision & Hearing,” advocating for active, healthy lifestyles and highlighting the importance ... for individuals with hearing impairments and shares the latest innovations in hearing aid ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... services and financial consultations to communities throughout the greater DC region, is inaugurating ... the goal of rescuing local animals and training them to be companions for ...
(Date:8/18/2017)... John, IN (PRWEB) , ... August 18, 2017 , ... ... to communities in northwest Indiana, is campaigning in support of Campagna Academy in a ... referred to as the “Hoosier Boys’ Town of Indiana,” Campagna Academy is a nonprofit ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
(Date:8/7/2017)... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced financial ... unless otherwise noted, are to the quarter ended June 30, ... 2017 Highlights include: Revenue of $1,126 ... Total prescriptions dispensed of 220,000, compared to 241,000 ... Gross profit per prescription dispensed of $371, ...
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
Breaking Medicine Technology: